- Home
- BAFN vs KRON Comparison
BAFN vs KRON Comparison
Compare BAFN & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- KRON
- Stock Information
- Founded
- BAFN 1999
- KRON 2017
- Country
- BAFN United States
- KRON United States
- Employees
- BAFN N/A
- KRON N/A
- Industry
- BAFN Savings Institutions
- KRON Medicinal Chemicals and Botanical Products
- Sector
- BAFN Finance
- KRON Health Care
- Exchange
- BAFN Nasdaq
- KRON Nasdaq
- Market Cap
- BAFN 55.4M
- KRON 55.5M
- IPO Year
- BAFN N/A
- KRON 2020
- Fundamental
- Price
- BAFN $13.08
- KRON $1.00
- Analyst Decision
- BAFN
- KRON Buy
- Analyst Count
- BAFN 0
- KRON 3
- Target Price
- BAFN N/A
- KRON $1.63
- AVG Volume (30 Days)
- BAFN 5.6K
- KRON 385.7K
- Earning Date
- BAFN 01-30-2025
- KRON 11-13-2024
- Dividend Yield
- BAFN 2.45%
- KRON N/A
- EPS Growth
- BAFN N/A
- KRON N/A
- EPS
- BAFN 0.72
- KRON N/A
- Revenue
- BAFN $76,217,000.00
- KRON $9,864,000.00
- Revenue This Year
- BAFN N/A
- KRON $62.21
- Revenue Next Year
- BAFN N/A
- KRON N/A
- P/E Ratio
- BAFN $17.76
- KRON N/A
- Revenue Growth
- BAFN 7.06
- KRON 146.48
- 52 Week Low
- BAFN $10.40
- KRON $0.69
- 52 Week High
- BAFN $15.05
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- BAFN 44.59
- KRON 57.04
- Support Level
- BAFN $12.94
- KRON $0.90
- Resistance Level
- BAFN $13.34
- KRON $0.97
- Average True Range (ATR)
- BAFN 0.40
- KRON 0.06
- MACD
- BAFN -0.01
- KRON 0.00
- Stochastic Oscillator
- BAFN 46.95
- KRON 78.57
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.